318 related articles for article (PubMed ID: 15816526)
1. The effect of cyclooxygenase-2 (COX-2) inhibition on human prostate cancer induced osteoblastic and osteolytic lesions in bone.
Gamradt SC; Feeley BT; Liu NQ; Roostaeian J; Lin YQ; Zhu LX; Sharma S; Dubinett SM; Lieberman JR
Anticancer Res; 2005; 25(1A):107-15. PubMed ID: 15816526
[TBL] [Abstract][Full Text] [Related]
2. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR
Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463
[TBL] [Abstract][Full Text] [Related]
4. Resistance of prostate cancer cell lines to COX-2 inhibitor treatment.
Wagner M; Loos J; Weksler N; Gantner M; Corless CL; Barry JM; Beer TM; Garzotto M
Biochem Biophys Res Commun; 2005 Jul; 332(3):800-7. PubMed ID: 15907789
[TBL] [Abstract][Full Text] [Related]
5. The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone.
Whang PG; Schwarz EM; Gamradt SC; Dougall WC; Lieberman JR
J Orthop Res; 2005 Nov; 23(6):1475-83. PubMed ID: 16005175
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of cyclooxygenase-2 activity by celecoxib does not lead to radiosensitization of human prostate cancer cells in vitro.
Ohneseit PA; Krebiehl G; Dittmann K; Kehlbach R; Rodemann HP
Radiother Oncol; 2007 Feb; 82(2):229-38. PubMed ID: 17207548
[TBL] [Abstract][Full Text] [Related]
7. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism.
Dai J; Keller J; Zhang J; Lu Y; Yao Z; Keller ET
Cancer Res; 2005 Sep; 65(18):8274-85. PubMed ID: 16166304
[TBL] [Abstract][Full Text] [Related]
8. The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer.
Miwa S; Mizokami A; Keller ET; Taichman R; Zhang J; Namiki M
Cancer Res; 2005 Oct; 65(19):8818-25. PubMed ID: 16204052
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity.
Kitagawa Y; Dai J; Zhang J; Keller JM; Nor J; Yao Z; Keller ET
Cancer Res; 2005 Dec; 65(23):10921-9. PubMed ID: 16322239
[TBL] [Abstract][Full Text] [Related]
10. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism.
Patel MI; Subbaramaiah K; Du B; Chang M; Yang P; Newman RA; Cordon-Cardo C; Thaler HT; Dannenberg AJ
Clin Cancer Res; 2005 Mar; 11(5):1999-2007. PubMed ID: 15756026
[TBL] [Abstract][Full Text] [Related]
11. The potential for a selective cyclooxygenase-2 inhibitor in the prevention of liver metastasis in human colorectal cancer.
Yamauchi T; Watanabe M; Hasegawa H; Nishibori H; Ishii Y; Tatematsu H; Yamamoto K; Kubota T; Kitajima M
Anticancer Res; 2003; 23(1A):245-9. PubMed ID: 12680220
[TBL] [Abstract][Full Text] [Related]
12. Involvement of cyclo-oxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines.
Ono K; Akatsu T; Murakami T; Kitamura R; Yamamoto M; Shinomiya N; Rokutanda M; Sasaki T; Amizuka N; Ozawa H; Nagata N; Kugai N
J Bone Miner Res; 2002 May; 17(5):774-81. PubMed ID: 12009007
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity.
Keller ET; Brown J
J Cell Biochem; 2004 Mar; 91(4):718-29. PubMed ID: 14991763
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer.
Goya M; Ishii G; Miyamoto S; Hasebe T; Nagai K; Yonou H; Hatano T; Ogawa Y; Ochiai A
Prostate; 2006 Nov; 66(15):1573-84. PubMed ID: 16927388
[TBL] [Abstract][Full Text] [Related]
15. Comparative intraosseal growth of human prostate cancer cell lines LNCaP and PC-3 in the nude mouse.
Soos G; Jones RF; Haas GP; Wang CY
Anticancer Res; 1997; 17(6D):4253-8. PubMed ID: 9494517
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2.
Sabino MA; Ghilardi JR; Jongen JL; Keyser CP; Luger NM; Mach DB; Peters CM; Rogers SD; Schwei MJ; de Felipe C; Mantyh PW
Cancer Res; 2002 Dec; 62(24):7343-9. PubMed ID: 12499278
[TBL] [Abstract][Full Text] [Related]
17. The bisphosphonate YM529 inhibits osteoblastic bone tumor proliferation of prostate cancer.
Yonou H; Ochiai A; Ashimine S; Maeda H; Horiguchi Y; Yoshioka K; Ogawa Y; Hatano T; Tachibana M
Prostate; 2007 Jun; 67(9):999-1009. PubMed ID: 17440967
[TBL] [Abstract][Full Text] [Related]
18. Effect of cyclooxygenase-2 (COX-2) inhibitors on prostate cancer cell proliferation.
Srinath P; Rao PN; Knaus EE; Suresh MR
Anticancer Res; 2003; 23(5A):3923-8. PubMed ID: 14666698
[TBL] [Abstract][Full Text] [Related]
19. Effects of the proteasome inhibitor bortezomib on osteolytic human prostate cancer cell metastases.
Whang PG; Gamradt SC; Gates JJ; Lieberman JR
Prostate Cancer Prostatic Dis; 2005; 8(4):327-34. PubMed ID: 16130017
[TBL] [Abstract][Full Text] [Related]
20. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells.
Lev-Ari S; Strier L; Kazanov D; Madar-Shapiro L; Dvory-Sobol H; Pinchuk I; Marian B; Lichtenberg D; Arber N
Clin Cancer Res; 2005 Sep; 11(18):6738-44. PubMed ID: 16166455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]